Pharmaceutical Manufacturing Facility, Thailand
SLP Environmental was appointed by a global pharmaceutical company to conduct a Phase 1 Environmental Site Assessment (Phase 1 ESA) at a pharmaceutical manufacturing facility located in Chachoengsao Province, Thailand. The Phase 1 ESA study was conducted in conformance with ASTM E1527-13 practice, and the primary objective was to assess whether there were any potential soil and groundwater contamination liabilities associated with the property on which the facility was situated.
Operations at the subject property comprised of the vaccine manufacturing as well as general administrative, QC laboratory and warehousing functions.
The scope of works comprised of a site and environs reconnaissance, interviews with key informants and desk study to assess the landuse history of the area and the physical and biological environmental setting.
These studies culminated in the determination of the environmental sensitivity of the project site area, and an assessment of the contaminative potential of neighboring properties.
SLP constructed a conceptual site model (CSM) for the subject property in order to examine potential linkages between sources of contamination and sensitive environmental receptors (e.g. soils, surface water groundwater and ecology), which aided in the determination as to whether any Recognised Environmental Conditions and/or De Minimis conditions (as defined under ASTM 1527) were associated with the subject property.